Ionis Pharmaceuticals, Inc.
IONS
Rang in aandelen
#2553
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Aandeelprijs
$45.20
Marktkapitalisatie
$7.51B
Verandering (1 dag)
1.85%
Verandering (1 jaar)
-38.55%
Land
US
Handel Ionis Pharmaceuticals, Inc. (IONS)
Categorie
Healthcare
Aantal uitstaande aandelen voor Ionis Pharmaceuticals, Inc. (IONS)
Aantal uitstaande aandelen per June 2026: 165.42M
Volgens de laatste financiële rapporten en de aandelenkoers van Ionis Pharmaceuticals, Inc. bedraagt het huidige aantal uitstaande aandelen 165.42M. Aan het einde van December 2023 had het bedrijf 143.00M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Ionis Pharmaceuticals, Inc. (IONS) van 2000 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 165.42M | 10.64% |
| 2024 | 149.51M | 4.56% |
| 2023 | 143.00M | 0.81% |
| 2022 | 141.85M | 0.59% |
| 2021 | 141.02M | 1.01% |
| 2020 | 139.61M | -0.28% |
| 2019 | 140.00M | 5.80% |
| 2018 | 132.32M | 6.70% |
| 2017 | 124.02M | 2.66% |
| 2016 | 120.80M | 1.26% |
| 2015 | 119.29M | 1.36% |
| 2014 | 117.69M | 6.51% |
| 2013 | 110.50M | 9.87% |
| 2012 | 100.58M | 0.92% |
| 2011 | 99.66M | 0.52% |
| 2010 | 99.14M | 1.05% |
| 2009 | 98.11M | 3.75% |
| 2008 | 94.57M | 12.93% |
| 2007 | 83.74M | 12.69% |
| 2006 | 74.31M | 18.18% |
| 2005 | 62.88M | 11.01% |
| 2004 | 56.64M | 2.13% |
| 2003 | 55.46M | 1.80% |
| 2002 | 54.48M | 23.51% |
| 2001 | 44.11M | 19.14% |
| 2000 | 37.02M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 253.90M | 53.49% |
US
|
|
| 396.00M | 139.39% |
US
|
|
| 478.91M | 189.51% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -62.41% |
NL
|
